Hodgkin lymphoma treatment for older persons in the modern era
Authors:
- 8 December 2023
- journal article
- research article
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2023 (1) , 483-499
Abstract
There has been a renewed effort globally in the study of older Hodgkin lymphoma (HL) patients, generating a multitude of new data. For prognostication, advancing age, comorbidities, altered functional status, Hispanic ethnicity, and lack of dose intensity (especially without anthracycline) portend inferior survival. Geriatric assessments (GA), including activities of daily living (ADL) and comorbidities, should be objectively measured in all patients. In addition, proactive multidisciplinary medical management is recommended (eg, geriatrics, cardiology, primary care), and pre-phase therapy should be considered for most patients. Treatment for fit older HL patients should be given with curative intent, including anthracyclines, and bleomycin should be minimized (or avoided). Brentuximab vedotin given sequentially before and after doxorubicin, vinblastine, dacarbazine (AVD) chemotherapy for untreated patients is tolerable and effective, and frontline checkpoint inhibitor/AVD platforms are rapidly emerging. Therapy for patients who are unfit or frail, whether due to comorbidities and/or ADL loss, is less clear and should be individualized with consideration of attenuated anthracycline-based therapy versus lower-intensity regimens with inclusion of brentuximab vedotin +/- checkpoint inhibitors. For all patients, there should be clinical vigilance with close monitoring for treatment-related toxicities, including neurotoxicity, cardiopulmonary, and infectious complications. Finally, active surveillance for “postacute” complications 1 to 10 years post therapy, especially cardiac disease, is needed for cured patients. Altogether, therapy for older HL patients should include anthracycline-based therapy in most cases, and novel targeted agents should continue to be integrated into treatment paradigms, with more research needed on how best to utilize GAs for treatment decisions.Keywords
This publication has 101 references indexed in Scilit:
- Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD studyBlood, 2012
- Treatment of Hodgkin lymphoma: the past, present, and futureNature Clinical Practice Oncology, 2008
- Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patientsBlood, 2008
- Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphomaLeukemia & Lymphoma, 2007
- A population-based cohort study on early-stage Hodgkin lymphoma treated with radiotherapy alone: with special reference to older patientsAnnals of Oncology, 2006
- Independent prognostic effect of co-morbidity in lymphoma patients: Results of the population-based Eindhoven Cancer RegistryEuropean Journal of Cancer, 2005
- Treatment of Elderly Hodgkin's Lymphoma Patients with a Novel 5-drug Regimen (ODBEP): A Phase II StudyLeukemia & Lymphoma, 2002
- Patients above Sixty Years Lymphoma Treated with a New Strategy of Age with Hodgkin'sActa Oncologica, 2002
- Long-term survival in Hodgkin's disease patientsEuropean Journal of Cancer, 2000
- A Prognostic Score for Advanced Hodgkin's DiseaseNew England Journal of Medicine, 1998